Ovarian Diseases
Information
- Disease name
- Ovarian Diseases
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00050414 | Completed | Phase 2 | A Study of Trabectedin in Patients With Advanced Ovarian Cancer | October 2002 | September 2005 |
| NCT00210249 | Completed | Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment | September 2002 | September 2008 | |
| NCT00816764 | Completed | Phase 1 | A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer | October 2008 | June 2010 |
| NCT01310647 | Completed | Phase 2 | Antral Follicle Priming Prior to ICSI (Intracytoplasmic Sperm Injection) in Previously Diagnosed Low Responders | June 2011 | February 2014 |
| NCT01460979 | Completed | Phase 2 | Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma | October 2011 | November 2015 |
| NCT01462890 | Completed | Phase 3 | Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer | November 2011 | December 2021 |
| NCT01566955 | Completed | N/A | Feasability Study of Removing the Ovaries and Fallopian Tubes | April 2012 | December 2014 |
| NCT01832116 | Completed | Phase 1 | 89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients | March 2013 | May 2014 |
| NCT02973750 | Completed | Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer | October 20, 2016 | July 18, 2020 | |
| NCT03562897 | Completed | Phase 2 | Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer | October 25, 2018 | June 15, 2022 |
| NCT03593681 | Completed | Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy | August 27, 2018 | February 14, 2020 | |
| NCT04209881 | Completed | Ovarian Reserve and Ankylosing Spondylitis | December 19, 2019 | May 19, 2020 | |
| NCT04807166 | Not yet recruiting | Phase 2 | Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer | June 1, 2021 | December 1, 2024 |
| NCT05048654 | Not yet recruiting | A Novel Ovarian Reserve Monitoring Algorithm for Patients at Risk of Ovarian Injury From Gonadotoxic Therapy | December 15, 2025 | June 30, 2029 | |
| NCT05753826 | Recruiting | Phase 2 | Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer. | August 1, 2023 | December 31, 2027 |
| NCT04519151 | Recruiting | Phase 2 | Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer | April 12, 2021 | November 2029 |
| NCT05617755 | Recruiting | Phase 1 | AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer | November 29, 2022 | February 2027 |
| NCT04189406 | Recruiting | Turner Syndrome Minipuberty Study | February 1, 2020 | December 1, 2024 | |
| NCT05001282 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | September 13, 2021 | June 15, 2025 |
| NCT01292733 | Terminated | Early Phase 1 | Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer | August 2009 | December 2015 |
| NCT01016054 | Terminated | Phase 1 | A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer | October 2009 | April 2010 |
| NCT04566952 | Unknown status | Phase 2 | Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer | October 28, 2020 | October 1, 2023 |
| NCT04579575 | Unknown status | Added Value of O-RADS in Evaluation of Ovarian Lesions | December 20, 2021 | October 1, 2022 | |
| NCT04556071 | Unknown status | Phase 2 | Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer | November 6, 2020 | October 1, 2022 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D010049